CeriBell (NASDAQ:CBLL) Issues Quarterly Earnings Results, Misses Expectations By $0.08 EPS

CeriBell (NASDAQ:CBLL) announced its earnings results on Tuesday. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08), Zacks reports.

CeriBell Stock Up 0.4 %

Shares of NASDAQ CBLL traded up $0.11 during mid-day trading on Tuesday, reaching $25.54. The company’s stock had a trading volume of 436,495 shares, compared to its average volume of 185,853. CeriBell has a 52 week low of $18.69 and a 52 week high of $32.75. The firm’s fifty day simple moving average is $23.47.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on CBLL shares. JPMorgan Chase & Co. initiated coverage on CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective for the company. Bank of America started coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target for the company. Canaccord Genuity Group raised their price objective on CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. TD Cowen boosted their price objective on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Canaccord Genuity Group started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $32.60.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.